TTRX
Income statement / Annual
Last year (2025), Turn Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Turn Therapeutics Inc.'s net income was -$3.19 M.
See Turn Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$52.74 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$52.74 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$265.57 K
|
$245.96 K
|
$7.50 K
|
$0.00
|
| General & Administrative Expenses |
$5.59 M
|
$1.55 M
|
$2.30 M
|
$4.21 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.59 M
|
$1.55 M
|
$2.30 M
|
$4.21 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$52.74 K
|
| Operating Expenses |
$5.86 M
|
$1.80 M
|
$2.31 M
|
$4.16 M
|
| Cost And Expenses |
$5.86 M
|
$1.80 M
|
$2.31 M
|
$4.21 M
|
| Interest Income |
$29.58 K
|
$28.71 K
|
$15.88 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$85.38 K
|
| Depreciation & Amortization |
$52.75 K
|
$47.48 K
|
$43.92 K
|
$52.74 K
|
| EBITDA |
-$3.14 M |
-$1.72 M |
-$2.25 M |
-$4.16 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.66 M
|
$28.71 K
|
$15.88 K
|
-$76.27 K
|
| Income Before Tax |
-$3.19 M
|
-$1.77 M
|
-$2.29 M
|
-$4.29 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$800.00
|
| Net Income |
-$3.19 M
|
-$1.77 M
|
-$2.29 M
|
-$4.29 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
-0.23 |
-0.13 |
-0.17 |
-0.33 |
| EPS Diluted |
-0.23 |
-0.13 |
-0.17 |
-0.33 |
| Weighted Average Shares Out |
$13.74 M
|
$13.42 M
|
$13.25 M
|
$13.18 M
|
| Weighted Average Shares Out Diluted |
$13.74 M
|
$13.42 M
|
$13.25 M
|
$13.18 M
|
| Link |
|
|
|
|
